Membrane-anchored CCL20 augments HIV Env-specific mucosal immune responses

Table 1 Immunization Regimens and Schedule

	Group 1	Group 2	Group 3
Boost Route	i.m.	i.n.	IV
	Gag VLPs	Gag VLPs	Gag VLPs,
4 Subgroups (10 mice/subgroup) Based on Vaccine	Gag/Env VLPs Gag/Env/CCL20 VLPs Gag/Env-CCL20 VLPs	Gag/Env VLPs Gag/Env/CCL20 VLPs Gag/Env-CCL20 VLPs	Gag/Env VLPs, Gag/Env/CCL20 VLPs Gag/Env-CCL20 VLPs
Schedule	One i.m prime followed by two i.m boosts at intervals of 4 weeks	One i.m prime followed by two i.n. boosts at intervals of 4 weeks	One i.m prime followed by two IV boosts at intervals of 4 weeks
Anti-CCL20 IgG	Three hours after each immunization	Three hours after each immunization	Three hours after each immunization

The mice were separated into three groups according to administration routes. Group 1, mice were immunized by one i.m prime followed by two i.m boosts with HIV VLPs. Group 2 or 3 mice were immunized by a single i.m prime followed respectively by two i.n or IV boosts with HIV VLPs. Within each of these groups, mice were further divided into four subgroups and immunized by different HIV VLPs

ISSN: 1743-422X